Feraheme

PreclinicalSmall molecule

SStanford University

Feraheme is one of 106 small molecule programs targeting Multiple Sclerosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

Kidney TransplantActive, not recruiting

MigraineActive, not recruiting

NanoparticleCompleted

Multiple SclerosisPreclinical

Active, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

MigrainePreclinical

Active, not recruiting

NanoparticlePreclinical

Completed

Competition

Competitive Landscape

145 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Cytoxan

BBaxter Healthcare Corporation

Phase 3

9 2

Versed

CConrado Roberto Hoffmann Filho

Phase 3

2 3

Zyrtec

KKenvue Brands

Phase 3

1 4

Vumerity

Biogen

Phase 3

4 5

Frexalimab

Sanofi

Phase 3

2 6

Clemastine Fumarate

Novartis

Phase 3

2 7

Activated Charcoal

Sanofi

Phase 3

1 8

Mayzent

Novartis

Phase 3

1 9

Antihistamine

Arrowhead Pharmaceuticals

Phase 3

2 10

Tolebrutinib

Sanofi

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Anemia1 trial

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

Terminated·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT02189889·5 enrolled

Multiple Sclerosis1 trial

High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases

Withdrawn·SStanford University··NCT01973517

Migraine1 trial

Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI

Completed·DDanish Headache Center·N/A·NCT02549898·34 enrolled

Osteomyelitis1 trial

Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI

Completed·HHeike E Daldrup-Link·Phase 2·NCT01336803·32 enrolled

Glioblastoma Multiforme1 trial

qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.

Completed·SSunnybrook Health Sciences Centre·Phase 1·NCT02466828·10 enrolled

3 more indications

Kidney Transplant1 trial

Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance

Completed·SStanford University·N/A·NCT02006108·21 enrolled

Nanoparticle1 trial

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

Completed·MM.D. Anderson Cancer Center·N/A·NCT01815333·10 enrolled

Intracranial Atherosclerosis1 trial

Predicting Stroke Risk in Intracranial Atherosclerotic Disease With Novel High Resolution, Functional and Molecular MRI Techniques

Withdrawn·NNorthwestern University·Approved·NCT05515874

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Feraheme. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Feraheme compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Feraheme. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SStanford University

Feraheme

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Anemia1 trial

Multiple Sclerosis1 trial

Migraine1 trial

Osteomyelitis1 trial

Glioblastoma Multiforme1 trial

Kidney Transplant1 trial

Nanoparticle1 trial

Intracranial Atherosclerosis1 trial

References

Drug Info

Quick Facts

Related News